Scarpelli Elisa, Capozzi Vito Andrea, Roberto Licia, Gallinelli Asya, Pezzani Alessandra, Monica Michela, Berretta Roberto
Department of Obstetrics and Gynecology, University Hospital of Parma, 43125 Parma, Italy.
Medicina (Kaunas). 2025 Jun 9;61(6):1058. doi: 10.3390/medicina61061058.
: Ectopic pregnancy (EP) is a potentially life-threatening condition and the leading cause of maternal mortality in the first trimester. Although both surgical and medical approaches are effective, selection criteria for Methotrexate (MTX) treatment remain inconsistent across international guidelines. Additionally, limited data on long-term reproductive outcomes are available. : We conducted a single-center retrospective cohort study of 107 patients diagnosed with tubal EP and treated at the Obstetrics and Gynecology Unit of the University Hospital of Parma between 2019 and 2023. MTX (50 mg/m) was offered to patients with β-hCG < 5000 mIU/mL, sac diameter < 40 mm, and no embryonic cardiac activity or hemoperitoneum; others underwent salpingectomy. Treatment outcomes, predictors of MTX success, and fertility outcomes were analyzed. : Medical treatment was offered to 36 patients (33.6%), with an overall success rate of 72%: in total, 20 resolved after a single dose and 6 after a second dose. Surgical conversion was necessary in 10 patients. The remaining 71 patients (66.4%) underwent primary salpingectomy. Initial β-hCG levels and gestational age did not significantly predict MTX failure ( 0.14 and 0.73, respectively), whereas gestational sac diameter was identified as a reliable predictor of treatment success ( = 0.01). In particular, a gestational sac maximum diameter of <2 cm emerged as a positive factor for MTX success (OR 1.13, 95% CI: 1.1-1.3, = 0.04). Among the 50 patients with follow-up data, 68% achieved a term live birth, with no significant difference between the MTX (52.9%) and surgical (75.8%) groups ( 0.12). Most of the pregnancies (90%) occurred spontaneously, while only 10% required assisted reproductive technologies. : MTX is a safe and effective treatment for tubal EP when patients are appropriately selected. Gestational sac diameter appears to be a reliable predictor of success. Both medical and surgical treatments yielded comparable reproductive outcomes, supporting individualized care models that prioritize fertility preservation.
异位妊娠(EP)是一种可能危及生命的情况,是孕早期孕产妇死亡的主要原因。虽然手术和药物治疗方法都有效,但甲氨蝶呤(MTX)治疗的选择标准在国际指南中仍不一致。此外,关于长期生殖结局的数据有限。
我们对2019年至2023年期间在帕尔马大学医院妇产科诊断为输卵管异位妊娠并接受治疗的107例患者进行了一项单中心回顾性队列研究。β - hCG < 5000 mIU/mL、孕囊直径 < 40 mm且无胚胎心搏或腹腔内出血的患者接受MTX(50 mg/m²)治疗;其他患者接受输卵管切除术。分析了治疗结局、MTX治疗成功的预测因素和生育结局。
36例患者(33.6%)接受了药物治疗,总体成功率为72%:其中,20例单次给药后治愈,6例二次给药后治愈。10例患者需要手术转换治疗。其余71例患者(66.4%)接受了初次输卵管切除术。初始β - hCG水平和孕周对MTX治疗失败无显著预测作用(分别为0.14和0.73),而孕囊直径被确定为治疗成功的可靠预测因素(P = 0.01)。特别是,孕囊最大直径 < 2 cm是MTX治疗成功的积极因素(OR 1.13,95% CI:1.1 - 1.3,P = 0.04)。在有随访数据的50例患者中,68%实现了足月活产,MTX组(52.9%)和手术组(75.8%)之间无显著差异(P = 0.12)。大多数妊娠(90%)为自然受孕,只有10%需要辅助生殖技术。
当患者选择适当时,MTX是治疗输卵管异位妊娠的一种安全有效的方法。孕囊直径似乎是成功的可靠预测因素。药物治疗和手术治疗产生了相似的生殖结局,支持优先考虑保留生育功能的个体化护理模式。